北京若生智能科技有限公司
Drug Database
FA

Factor VIIa (AryoSeven)

✓ Approved

AryoGen Pharmed · F7 · 重组蛋白

什么是 Factor VIIa？

Factor VIIa 是一种重组蛋白，由AryoGen Pharmed研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名AryoSeven
公司AryoGen Pharmed
药物类别重组蛋白, 细胞治疗
分子靶点F7
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, AryoGen Pharmed

作用机制

分子靶点

Factor VIIa 作用于 1 个分子靶点：

F7coagulation factor VII (SPCA)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

Factor VIIa 针对 4 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersExtravasation blood✓ Approved
Congenital, familial and genetic disordersFactor IX deficiency✓ Approved
Congenital, familial and genetic disordersFactor VIII deficiency✓ Approved
Vascular disordersHaemorrhage✓ Approved

相关研究文献

PubMedInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026-10-26

Recombinant activated factor VIIa for severe postpartum hemorrhage in Africa: Evidence, appropriate use, and research priorities-A narrative review.

Mahlangu Johnny J, Rhemtula Haroun H, Zamparini Jarrod J, Chauke Lawrence L

Postpartum hemorrhage (PPH) accounts for 30%-50% of maternal mortality in Africa and occurs in the context of pre-existing anemia, limited blood product availability, delayed recognition, and constrained referral systems. Although bundle-based care (E-MOTIVE), early tranexamic acid (TXA), and uterotonics have substantially improved outcomes, a small proportion of women develop refractory hemorrhage despite optimal conventional management. This narrative review evaluates the role of recombinant activated factor VIIa (rFVIIa) in severe PPH within the African context. We conducted a structured search of PubMed/MEDLINE, Embase, Scopus, and Google Scholar, which was supplemented by manual review of international guidelines. We critically evaluated and synthesized data from clinical studies, systematic reviews, registries, consensus statements, and relevant African literature. The principal evidence derives from a French-Swiss randomized controlled trial demonstrating a 40% relative reduction in invasive procedures, supported by observational studies and expert consensus. In 2022, the European Medicines Agency approved rFVIIa for severe PPH after uterotonic failure, followed by South African approval in 2023. The indication remains unapproved by the U.S. Food and Drug Administration and is off-label in most other African countries. Efficacy depends on timely administration after definitive obstetric source control and correction of coagulopathy and physiological derangements. Current evidence supports rFVIIa as a protocolized rescue adjunct rather than routine therapy. In Africa, its use should be restricted to carefully selected women with refractory PPH managed in tertiary centers with multidisciplinary expertise. African registries, pragmatic implementation studies, and health-economic evaluations are needed to define its optimal role within resource-constrained healthcare systems.

PMID 42929449
阅读全文 →
PubMedBiologics : targets & therapy2026-10-26

What's New and What's Next for Emicizumab for the Treatment of Hemophilia A?

Mahlangu Johnny N JN

Emicizumab, a bispecific factor VIIIa-mimetic antibody, has transformed hemophilia A prophylaxis by providing an effective subcutaneous treatment regardless of factor VIII inhibitor status. The HAVEN program established sustained reductions in treated bleeding, favorable safety, and reduced treatment burden across children and adults. More recent evidence has expanded its use into infancy, previously untreated patients, and selected people with moderate or mild hemophilia A, shifting treatment toward prevention before recurrent bleeding and joint damage occur. Real-world experience broadly confirms the trial's efficacy but also highlights important limitations. Zero treated bleeds does not necessarily indicate absence of pain, synovitis, or progressive arthropathy. At the same time, breakthrough bleeding, laboratory assay interference, rare neutralizing anti-drug antibodies, and thrombotic complications associated principally with excessive activated prothrombin complex concentrate remain clinically relevant. Emicizumab controls bleeding in patients with factor VIII inhibitors but does not induce immune tolerance, leaving unresolved questions regarding inhibitor eradication, delayed factor VIII exposure, and optimal induction of immune tolerance. The next phase of development will require moving beyond uniform weight-based dosing and annualized bleeding rates toward individualized exposure, validated biomarkers, and outcomes that encompass joint structure, physical participation, quality of life, and treatment burden. Emicizumab must also be positioned against next-generation factor VIII mimetics, rebalancing therapies, sustained-exposure factor VIII replacement, and gene therapy. This review critically examines the established and emerging evidence, practical management challenges, unresolved scientific questions, and future therapeutic positioning of emicizumab. Its ultimate impact will depend not only on broader eligibility, but also on precision use, long-term safety, rational treatment sequencing, and equitable global access.

PMID 42928872
阅读全文 →
PubMedJournal of biochemical and molecular toxicology2026-10-26

Theranekron Attenuates Inflammation, Oxidative Stress Index, and Apoptosis in Lipopolysaccharide-Induced Cardiovascular Toxicity: Association With Hypoxia-Inducible Factor-1 Alpha-Related Gene Expression.

Savran Mehtap M, Asci Halil H, Imeci Orhan O, Oguzlar Furkan Cagri FC et al.

This study aimed to evaluate the possible protective effects of Theranekron, an extract derived from Tarantula cubensis venom, on cardiovascular damage induced by lipopolysaccharide (LPS) in an experimental rat model. A total of 32 male Wistar Albino rats were randomly divided into 4 groups: Control, Lipopolysaccharide, Lipopolysaccharide plus Theranekron, and Theranekron alone. Lipopolysaccharide administration caused pronounced histopathological changes in the heart and aorta, including endothelial sloughing, hyperemia, hemorrhage, and infiltration of inflammatory cells. These pathological findings were accompanied by elevated oxidative stress markers, increased tumor necrosis factor-alpha and inducible nitric oxide synthase immunoreactivity, and increased caspase-3 immunoreactivity. Additionally, genes associated with the hypoxia-inducible factor-1 alpha (HIF-1α) pathway-such as interleukin 6, signal transducer and activator of transcription 3 (STAT3), and vascular endothelial growth factor-were significantly upregulated in the lipopolysaccharide group. Theranekron pretreatment was associated with partial attenuation of oxidative stress imbalance, of inflammatory and apoptotic immunoreactivity, and of the upregulation of HIF-1α-related transcripts. Overall, these findings suggest that Theranekron may offer partial protection against early LPS-induced cardiovascular injury.

PMID 42929009
阅读全文 →
PubMedAutophagy2026-10-26

AKT1-phosphorylated TERT assembles a FOXO3-MYC transcriptional complex that drives ERphagy and proteostasis in post-mitotic RPE.

Babu Vishnu Suresh VS, Ghosh Sayan S, Bammidi Sridhar S, Jiwon Ryu R et al.

The retinal pigment epithelium (RPE) sustains lifelong proteostasis under chronic stress, yet how post-mitotic cells activate macroautophagy/autophagy when canonical kinase pathways suppress it remains unresolved. Here we demonstrate that AKT1 (protein kinase B alpha), drives autophagy through a non-canonical transcriptional mechanism triggered by isoform imbalance. In RPE and age-related macular degeneration (AMD) models, AKT2 (protein kinase B beta) hyperactivation destabilizes MTORC2 (mechanistic target of rapamycin complex 2) and engages RPS6KB/S6K (ribosomal protein S6 kinase beta) -mediated IRS-1 (insulin Receptor Substrate 1) inhibition, creating a feedforward autophagic arrest. Compensatory AKT1 activation via MTORC2 phosphorylates TERT (telomerase reverse transcriptase) at serine 824, driving nuclear translocation that is independent of telomere maintenance. In the nucleus, TERT assembles with FOXO3 (forkhead Box O3) and MYC (MYC proto-oncogene, bHLH transcription factor) into a tripartite transcriptional complex that occupies the EIF2AK3/PERK promoter (eukaryotic translation initiation factor 2-alpha kinase 3/ protein kinase R-like endoplasmic reticulum kinase), enabling EIF2AK3 transcriptional activation. This activity converts the unfolded protein response from pro-apoptotic to cytoprotective: EIF2AK3-ATF4 (activating transcription factor 4) signaling promotes core autophagy machinery biogenesis and selective ERphagy through the receptors TEX264 (testis expressed 264) and CCPG1(cell cycle progression 1), which prevents pathological EIF2AK3 clustering and preserves tubular ER architecture in diseased RPE. Using C. elegans phosphorylation-deficient mutants, mouse models and AMD patient iPSC-RPE, we establish that AKT1-mediated TERT phosphorylation is an evolutionarily conserved prerequisite for FOXO/DAF-16 nuclear function and lysosomal homeostasis in post-mitotic cells, offering therapeutic potential through targeted pharmacologic inhibition of AKT2.Abbreviations: ACTB: actin, beta; AKT1: AKT serine/threonine kinase 1; AKT2: AKT serine/threonine kinase 2; ALP: autophagy-lysosomal pathway; AMD: age-related macular degeneration, ATF4: activating transcription factor 4; ATG3: autophagy related 3; ATG4B: autophagy related 4B cysteine peptidase; ATG7: autophagy related 7; CCPG1: cell cycle progression 1; CFH: complement factor H; C57BL/6J: C57 black 6J; DMSO: dimethyl sulfoxide; MYC: MYC proto-oncogene, bHLH transcription factor; EIF2A/eIF2α: eukaryotic translation initiation factor 2A; EIF2AK3/PERK: eukaryotic translation initiation factor 2 alpha kinase 3; ER: endoplasmic reticulum; ERN1/IRE-1α: endoplasmic reticulum to nucleus signaling 1; ERphagy: endoplasmic reticulum-selective autophagy; FOXO1: forkhead box O1; FOXO3: forkhead box O3; iPSC-RPE: induced pluripotent stem cell-derived retinal pigment epithelium; ITGB1/integrin β1: integrin subunit beta 1; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAPKAP1/SIN1: MAPK associated protein 1; MTOR: mechanistic target of rapamycin kinase; MTORC1: MTOR complex 1; MTORC2: MTOR complex 2; PBS: phosphate-buffered saline; PI3K: phosphoinositide 3-kinase; RICTOR: RPTOR independent companion of MTOR complex 2; RPE: retinal pigment epithelium; RPTOR: regulatory associated protein of MTOR complex 1; SQSTM1/p62: sequestosome 1; TERT: telomerase reverse transcriptase; TEX264: testis expressed 264, ER-phagy receptor; UPR: unfolded protein response; VCL: vinculin; WT: wild type.

PMID 42929416
阅读全文 →
PubMedAnnals of surgery2026-10-26

Prior Biliary Drainage Procedure Is a Near-universal Risk Factor for Postoperative Hepatic Abscess After Liver Resection.

Martinet-Kosinski Florian F, Badon-Murgue Flora F, Sauvanet Pierre P, Buc Emmanuel E

PMID 42928076
阅读全文 →
PubMedJournal of children's orthopaedics2026-10-26

Letter to the editor regarding "Risk factor analysis for growing pains in children: results of parental survey".

Fallahi Sahand S, Silva-Mendoza Diego D

PMID 42928751
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多Factor VIIa